INS and type 2 diabetes mellitus: The development of absolute insulin deficiency in Type 2 diabetes will alter treatment: oral hypoglycaemic agents (especially sulphonylureas) will not be effective, the newer agents, e.g. glucagon‐like peptide (GLP)‐1 receptor analogues and dipeptidyl peptidase (DPP)4 inhibitors, are not suitable, and the most appropriate insulin regimen may be basal‐bolus rather than background long‐acting insulin.